chrisvoncsefalvay/vaers-outcomes huggingface dataset:
After receiving 2nd dose of Pfizer's vaccine, had pain relief as well, short term.; This is a spontaneous report from a contactable healthcare professional, the patient. A 38-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL3302) via an unspecified route of administration in the left arm on 26Jan2021 (at the age of 38-years-old) as a single dose for COVID-19 immunisation. Medical history included GERD, allergies, bee sting hypersensitivity (bees), contrast media allergy (contrast dye), chronic pain, injury at the age of 16 and COVID-19 in Oct2020. Prior to the vaccination, the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included ibuprofen (MANUFACTURER UNKNOWN), cetirizine hydrochloride (ZYRTEC) and omeprazole (MANUFACTURER UNKNOWN); all taken for unknown indications from unknown dates and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL0140) via intramuscular route of administration in the left arm on an unknown date in Jan2021 at 14:00 (at the age of 38-years-old) as a single dose for COVID-19 immunisation. On 26Jan2021 at 14:00, the patient had short term pain relief. The patient had lived with chronic pain for 22 plus years of life due to an injury at age 16. She actually had COVID-19 in October 2020 and about 6-7 days into it, had chronic pain relief for about 1 week. She felt no every day pain. After receiving the second dose of Pfizer's vaccine, she had pain relief as well, short term. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the reported event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event lived with chronic pain for 22 plus years of life due to an injury at age 16 and after receiving 2nd dose of Pfizer's vaccine, pain relief as well, short term was recovered on an unknown date in 2021.   No follow-up attempts are needed. No further information is expected.
Felt sore arm (deltoid), developed headache (20 hours after vaccine), body aches, chills (developed 30 hours after vaccine).  Temp 100.1, (approx 32 hours after vaccine).   All resolved 43 hours after vaccine.
Vomiting that started around 11 hours after dose. 3 episodes.  Lastly roughly 5 hours.  Slowly improved.  At 24 hours, still feels nauseous but feels better.  No more vomiting.
C/o dizziness, feeling anxious, mild diaphoresis. Drank water, laid with feet up, rested for 5 min. Vitals stable. Stated "felt better" after 5 min of rest and opted to leave on her own.
Patient developed renal infarct May 4, 2021.  No previous history of thromboembolic disease.  He subsequently developed severe upper chest pain and fatigue with an elevated high-sensitivity troponin I greater than 1000.  He had cardiac catheterization on May 17,2021 which revealed nonobstructive coronary artery disease.  His inflammatory markers are elevated (CRP, sed rate).  He is scheduled for cardiac MRI to look for inflammatory disease of the heart.  The patient himself is wondering if these events could be triggered by the COVID-19 vaccine he received.
Severe migraine; Chills; Fever of 101.4; This spontaneous case was reported by a consumer and describes the occurrence of MIGRAINE (Severe migraine), CHILLS (Chills) and PYREXIA (Fever of 101.4) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Unknown) for COVID-19 vaccination.     No Medical History information was reported.    On 14-Sep-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 14-Sep-2021, the patient experienced MIGRAINE (Severe migraine), CHILLS (Chills) and PYREXIA (Fever of 101.4). At the time of the report, MIGRAINE (Severe migraine) outcome was unknown and CHILLS (Chills) and PYREXIA (Fever of 101.4) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Body temperature: 101.4 (High) fever of 101.4.         Patient took the second dose of moderna shot and within couple of hours  No concomitant and treatment medications were provided   Reporter did not allow further contact
(L) Deltoid - swollen, red AMOXICILLIN RX started w/DTAP.
Full body hives (urticaria) beginning 10 days after Moderna booster. Itchy, hot, migrating from body part to body part. Symptoms have lasted 15 days so far. Minimally responsive to antihistamines.
vaccinated person got coronavirus; This spontaneous case was reported by a nurse and describes the occurrence of COVID-19 (vaccinated person got coronavirus) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced COVID-19 (vaccinated person got coronavirus). At the time of the report, COVID-19 (vaccinated person got coronavirus) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, SARS-CoV-2 test: positive (Positive) positive.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant and treatment medication reported.  Consumer calling asking about the new variant, the Omicron variant, and how someone, who was double vaccinated and received the booster dose, got the omicron variant of the coronavirus.  Company comment: This is a spontaneous  case concerning a  male patient of an unknown age with no medical history reported, who experienced unexpected event of COVID 19 (AESI). The event occurred on an unknown date after the third dose of mRNA-1273 vaccine. Clinical course and treatment details were not provided. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.; Sender's Comments: This is a spontaneous  case concerning a  male patient of an unknown age with no medical history reported, who experienced unexpected event of COVID 19 (AESI). The event occurred on an unknown date after the third dose of mRNA-1273 vaccine. Clinical course and treatment details were not provided. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.
RA; Joint pain/symptoms of RA; Swelling in hands and upper extremities/symptoms of RA; Stiffness in hands and upper extremities; This case was reported by a physician via call center representative and described the occurrence of rheumatoid arthritis in a 77-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 18th December 2018, the patient received the 2nd dose of Shingrix. On an unknown date, less than a year after receiving Shingrix, the patient experienced rheumatoid arthritis (serious criteria GSK medically significant), joint pain, peripheral swelling and limbs stiffness. On an unknown date, the outcome of the rheumatoid arthritis was not recovered/not resolved and the outcome of the joint pain, peripheral swelling and limbs stiffness were unknown.   It was unknown if the reporter considered the rheumatoid arthritis, joint pain, peripheral swelling and limbs stiffness to be related to Shingrix.  Additional details were received as follows: The patient experienced joint pain, swelling and stiffness in hands and upper extremities.  The physician reported that, the patient had symptoms of rheumatoid arthritis (RA) and had RA as of February 2019. The physician called in just to report adverse event.
Fever 106 approx 2.5hrs p/immun, vomiting x 2, sx resolving w/in 3 hrs of initial sx; cyanotic lips, hands, feet; Md contacted @ 215-call returned @ 345; rx gatorade; APAP;
Patient had a tingling and slight pain on the bottom back of her right arm about two weeks after she got the vaccination (same arm she received COVID vaccine). She went to the emergency room and they concluded the COVID vaccine could have reactivated the shingles virus and she had a shingles infection. There was no rash.  They prescribed her Valtrex 1 gram three times a day.
Began running a fever, cough, and complaining of pain at the roof of the mouth.  White coating on tongue.
Developed Belle's Palsey on left side of face exactly one week after first shot.  Doctor says it may or may not come from the vaccine.
Symptoms started occurring about 3 hours after the vaccines. It started with sore arms then lead to headache sore legs and fever.
This spontaneous report was received from a physician refers to a 48 year old male patient. The patient was vaccinated with a dose of 0.5 ml PNEUMOVAX 23. On an unknown date, the patient experienced high fever of 104 degrees, aches and pain, dizziness and excruciating pain in the armpit area after receiving the vaccination. The outcome of the events were unknown at the time of this report. This is one of the several reports received by the same reporter. Additional information has been requested.
late second doses / received his first dose on Dic 2020 / due Covid situation.; This case was reported by a pharmacist via call center representative and described the occurrence of social problem in an unspecified number of patients who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (1st dose received on an unknown date).   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced social problem. On an unknown date, the outcome of the social problem was unknown.  Additional details were provided as follows: The age at vaccination was not applicable for this report. The pharmacist stated that, the patients were late for 2nd dose of Shingrix due to covid situation. This case was linked with case US2021142802, reported by same reporter for different patient. The reporter did not consent to follow up.; Sender's Comments:  US-GLAXOSMITHKLINE-US2021142802:same reporter
Following day, a little over 24 after dose was administered, I felt very loopy, almost as if I were drunk. My speech was noticeably slowed/slurred, I had a sleepy like gaze, my reactions were slower than normal, standing or walking it felt like I was floating, and not only did I feel this, but my husband noticed it as well. This only lasted for an hour or two. 48 hours after dose was administered, I felt "sick," I was very fatigued and spent most of the day in bed. I was not actually sick. I had no fever or any other symptoms of illness other than general unwellness. Arm was only sore whenever I first woke up or had not moved it for a while. I maintained a full range of motion despite my arm being sore during the times I mentioned. This lasted for no more than 72 hours.
Patch of erythema on R anterior thigh with mild induration palpable warmth and some tenderness. Patient walking with a limp.
Moderna COVID-19 Vaccine EUA Headache, scratchy throat, tight chest, slight labored breathing, cough, chills, sweats, muscle aches, fatigue - all symptoms continued for over a week
Henoch Schonlein purpura - Rash onset 11/30/09. Phone call 12/1/09
High fever of 106F. Took to ER and was put on ice to bring temperature down. Stopped talking and walking. Did not resume walking. 4 months later, had "2 words" vocabulary; then went to none. Dx'd as PDD/Autism about 4 years ago. Follow up on 01/16/2001: "No doctor ever gave Lot #'s on any vaccines.  We have moved to Indiana from Michigan."
Nausea, vomiting, temp 105 went to ER for labs, IV fluids, WBC increased 20.
Feeling unwell; Nausea; Headaches; Significant redness and swelling at the injection site; Significant redness and swelling at the injection site; This non-serious case was reported by a nurse via call center representative and described the occurrence of injection site swelling in a 18-year-old female patient who received Men B NVS (Bexsero) (batch number PX7E2, expiry date 30-SEP-2026) for prophylaxis.   On 22-SEP-2023, the patient received Bexsero (right deltoid). In SEP-2023, an unknown time after receiving Bexsero, the patient experienced injection site swelling (Verbatim: Significant redness and swelling at the injection site) and injection site erythema (Verbatim: Significant redness and swelling at the injection site). On an unknown date, the patient experienced feeling unwell (Verbatim: Feeling unwell), nausea (Verbatim: Nausea) and headache (Verbatim: Headaches).The outcome of the injection site swelling, injection site erythema, feeling unwell, nausea and headache were unknown.   The reporter considered the injection site swelling, injection site erythema, feeling unwell, nausea and headache to be possibly related to Bexsero and Bexsero Pre-Filled Syringe Device.  The company considered the injection site swelling, injection site erythema, feeling unwell, nausea and headache to be possibly related to Bexsero and Bexsero Pre-Filled Syringe Device.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date: 03-OCT-2023 The reporter was a nurse form a clinic who stated a patient received Bexsero in her right deltoid and a day later the patient noticed swelling and redness at the injection site but the clinic was not notified until days later.  The patient was seen the day before reporting at the clinic and had a significant swelling and redness at the injection site, patient was feeling unwell with headache and nauseas.  The treating physician believed that the patient was having an adverse event related to the vaccine.  The reporter consented to follow up.
Hospital discharge dx was "diarrhea of presumed infectious origin". Treatment included IV antibiotics. Diagnosed with bacterial diarrhea, Dehydration, Hypocalcemia, Hypokalemia
Pt developed hives to entire body and a mild fever. He used Benadryl x 3 days.
This spontaneous report as received from a pharmacist refers to an unspecified patient of unknown age and gender. Information about the patient's medical history and concurrent conditions was not reported. On 29-AUG-2015, the patient was vaccinated with an improperly stored dose of ZOSTAVAX Lot number reported as "L000416", expiration date: 08-MAR-2016 (administration route was not provided). No concomitant therapies were reported. No adverse effects were reported. Additional information has been requested.
This spontaneous report was received from the office manager refers to 12 week old male patient. The patient's concurrent conditions, medical history, drug reactions, allergies and concomitant medications were not reported. On 17-OCT-2017, the patient was vaccinated with improperly stored doses of ROTATEQ orally, lot# M038209 with an expiration date 23-APR-2018 and lot# M041768 with an expiration date 25-JUN-2018. (dose was not reported). Reporter stated that the vaccine was deemed stable. There was no adverse effect reported. No product quality complaint was involved. Administered doses of vaccine experienced the temperature excursion from 32 degrees Fahrenheit to 35 degrees Fahrenheit for 27 hours. Data logger was involved. There were previous excursions reported (from 32 degrees Fahrenheit to 35 degrees Fahrenheit for 27 hours and form 47 degrees Fahrenheit to 77 degrees Fahrenheit for 27 hours). This is one of the report received from the same reporter.
This is a spontaneous report received from a contactable consumer or other non-HCP (patient). A male patient received the 1st dose of BNT162B2 (Pfizer-BioNTech COVID-19 vaccine, batch/lot# unknown), single dose, for COVID-19 immunisation. Medical history and concomitant medications not reported. The patient experienced peripheral swelling (arm swollen big/arms got real big), and musculoskeletal stiffness (arms got real big/really tight and hard), with outcome of unknown. Additional information: Patient stated, "My arm is swelling big. It is getting pretty big. It is my first dose and my arms got real big. It is really tight and hard." Follow-up attempts completed. No further information expected.
Vestibular migraine; hyperacusis; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 32 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), intramuscular, administered in arm right, administration date 15Oct2021 11:30 (Lot number: EW0217) at the age of 32 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "known allergies: Mango" (unspecified if ongoing). Concomitant medication(s) included: FLONASE [FLUTICASONE PROPIONATE]; FLU, administration date 15Sep2021. Vaccination history included: Bnt162b2 (Dose Number: 2, Batch/Lot No: EN6203, Location of injection: Arm Right, Vaccine Administration Time: 01:15 AM, Route of Administration: Intramuscular), administration date: 25Feb2021, when the patient was 32 years old, for COVID-19 immunization; Bnt162b2 (Dose Number: 1, Batch/Lot No: EK4176, Location of injection: Arm Left, Vaccine Administration Time: 10:00 AM, Route of Administration: Intramuscular), administration date: 13Jan2021, when the patient was 31 years old, for COVID-19 immunization. The following information was reported: VESTIBULAR MIGRAINE (non-serious) with onset 15Oct2021 15:00, outcome "not recovered", described as "Vestibular migraine"; HYPERACUSIS (non-serious) with onset 15Oct2021 15:00, outcome "not recovered", described as "hyperacusis". The events "vestibular migraine" and "hyperacusis" were evaluated at the physician office visit.  Additional information: Prior to vaccination, the patient was not diagnosed with COVID-19, and since the vaccination patient not diagnosed with COVID-19.  No follow-up attempts are possible. No further information is expected.
Information has been received from an office manager concerning a 65-year-old female with allergic reaction to tetracycline, codeine, morphine, naprosyn and fentanyl, who on 02-MAY-2007 was vaccinated subcutaneously with a "single dose vial" of ZOSTAVAX (lot # 656395/0290U). Concomitant therapy included CRESTOR, estrogens (unspecified) and "lipid medication" (therapy unspecified). On an unspecified date the patient developed "shingles pain" at her abdomen. The patient sought medical attention via an office visit with a physician. No diagnostic labs were performed. At the time of the report the patient's status was recovering. A product quality complaint was not involved. Additional information has been requested.
Fever to 102  associated with chills, fatigue,  started about 5 hours after 2nd dose of pfizer vaccination on 6/25/21
Lupus and Idiopathic pulmonary fibrosis; Lupus and Idiopathic pulmonary fibrosis; patient had fever, had short of breath, had terrible dry cough; like when having flares; Was short of breath; terrible dry cough; Fever; This is a spontaneous report from a contactable consumer (patient). A female patient of an unspecified age received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE Solution for injection, lot no. and expiry date not reported), via an unspecified route of administration on 21Jan2021 at a single dose for covid-19 immunization.  Medical history included Lupus and Idiopathic pulmonary fibrosis. She takes Hydroxychloroquine and Mycophenolate 50 mg for it. The patient's concomitant medications were not reported. On Jan2021, 3 days after vaccine administration, patient had fever, had short of breath, had terrible dry cough; like when having flares. She wanted to know should she take the second dose or not. She also asked the protection percentage after the first dose. Outcome of the events was unknown.   Information about lot/batch number has been requested
COUGH, SOB, HX OF MOTHER BEING POSITIVE FOR COVID, PT TESTED POSITIVE FOR COVID
Headache, Myalgia, Fever, NauseaVomiting, chills, sweats, neck and back pain Narrative: Night of vaccine had sweats and chills, the following day had neck/back pain, had a low grade fever and today states is feeling "fine". Symptoms have resolved. Took Tylenol and alternated with Ibuprofen both OTC.
brain aneurism; This spontaneous case was reported by an other health care professional and describes the occurrence of INTRACRANIAL ANEURYSM (brain aneurism) in an adult female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced INTRACRANIAL ANEURYSM (brain aneurism) (seriousness criteria death and medically significant). The reported cause of death was brain aneurism. It is unknown if an autopsy was performed.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication details were provided.  It was reported that the person around it's 30's died from a brain aneurism right after receiving the Moderna Vaccine.   No treatment information was mentioned.  This case concerns female patient of unknown age with no relevant medical history reported, who experienced the unexpected event of intracranial aneurysm. The event occurred on an unknown number of days after the first dose of mRNA-1273 and had a fatal outcome on an unknown date. No autopsy report was provided. The rechallenge was not applicable, as the event happened after the first dose. The benefit-risk relationship of mRNA-1273 is not affected by this report.  Further information was requested.; Sender's Comments: This case concerns female patient of unknown age with no relevant medical history reported, who experienced the unexpected event of intracranial aneurysm. The event occurred on an unknown number of days after the first dose of mRNA-1273 and had a fatal outcome on an unknown date. No autopsy report was provided. The rechallenge was not applicable, as the event happened after the first dose. The benefit-risk relationship of mRNA-1273 is not affected by this report.  Further information was requested.; Reported Cause(s) of Death: brain aneurism
Heart racing, fainting (even while laying down), cold sweats. The alarming part was my heart and the fainting response even while laying down.
Numbing in left arm for 2 weeks (intermittent). Chest tightness after 24 hours (lasted 3 weeks).
On September 1, 2018, 8 days after receiving the SHINGRIX Vaccine I started having intermittent sharp pains on the right side of my face. These pains worsened over the next day and I went to Urgent Care on September 2, 2018. I was diagnosed with trigeminal neuralgia and referred for follow-up in the neurology department. On September 6 I was examined by Dr. in the neurology department. Based on my symptoms, he diagnosed my condition as "classic trigeminal neuralgia" and referred my for an MRI to rule out a brain tumor. The MRI was normal. At the advice of my primary care doctor, I received the second dose on SHINGRIX in December 2018. As the symptoms are not severe (and are less server than the initial onset) I have not yet started the recommended medication. Although the timing of the onset of my condition (8 days after administration of the vaccine) could be coincidental, I strongly believe that it also may be a side effect of the SHINGRIX, as zoster herpes is nerve related.
Patient received the vaccine on 04/29/2022. He didn't start to feel symptoms until 05/03/2022. He stated that he got the shivers, body aches, vision changes, light sensitive, and disoriented. The symptoms subsided by 05/04/2022. He states that he has no remainging symptoms.
5 X 5" area of erythema to (R) thigh started day after vaccine, warm to touch. Non tender no drainage.